Endsulin

Executive Summary

Endsulin is pioneering a liver-directed gene therapy for Type 1 Diabetes (T1D), aiming to eliminate the need for daily insulin injections and immunosuppression. The company's proprietary approach genetically engineers liver cells to produce and regulate insulin in response to blood glucose levels, offering a potential single-administration cure for T1D. Founded in 2018 and based in San Diego, Endsulin operates in the RNA & Gene Therapy and Viral Technology sectors. The company's stage is listed as 'Approved', which likely reflects a de-risked preclinical or regulatory milestone, though specific development status is undisclosed. Endsulin's technology addresses a massive unmet need, with T1D affecting millions globally. The gene therapy field's recent successes, particularly in liver-directed indications, provide a favorable tailwind. However, as a private, early-stage company with no disclosed funding rounds or valuation, Endsulin faces significant risks, including manufacturing challenges, long-term durability of gene expression, and potential safety issues. The company's path to clinical validation and commercialization remains uncertain, but its differentiated approach could be transformative if successful.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data Release65% success
• Q1 2027Regulatory Filing for IND/CTA40% success
• TBDPartnership or Licensing Deal with Major Pharma30% success